Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vakcina Kft.

Latest From Vakcina Kft.

Morningside Group

BioPharmaceutical China

In HIV Research, A Race For The Cure Is Back On Track

Hopes for a vaccine or cure for HIV/AIDS have been dashed before. But recent scientific advances and greater understanding of the limits of antiretroviral drugs have reignited optimism. Just don't expect VCs to get on board.

2011 Scrip 100: All to play for as new technologies shake up the vaccines market

New antigen types, novel delivery systems and a shift away from the low-hanging fruit towards more problematic conditions point to healthy prospects in the vaccines space, writes Dr Peter Charlish.

Infectious Diseases Cancer

Selecta raises "opportunistic" financing for nanoparticle vaccine development

Selecta Biosciences has raised $15 million in an "opportunistic" series C financing. OrbiMed Advisors led the round, with existing investors Polaris Venture Partners, Flagship Ventures, NanoDimension and Leukon Investments also participating.

Companies Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • Vaccine Ltd.
UsernamePublicRestriction

Register